Diana F. Clarke, PharmD
Assistant Professor
Boston University Chobanian & Avedisian School of Medicine
Pediatrics
Infectious Diseases

PharmD, State University of New York at Buffalo
BS, University of Rhode Island College of Pharmacy



Diana Clarke, Pharm.D., is an Assistant Professor of Pediatrics in Infectious Diseases at the Chobanian and Avedisian School of Medicine and Pediatric HIV Pharmacotherapy Specialist at Boston Medical Center. She works in the Pediatric ID clinic and the High-Risk OB clinic where she is actively involved in the management of children and pregnant women living with HIV. Her commitment to pediatrics is demonstrated through her memberships to the WHO Pediatric Antiretroviral Working Group and as a Consultant, Human Resources and Services Administration, HIV/AIDS Bureau (HRSA) for the DHHS Pediatric and Perinatal HIV Guidelines Committees. Her research interests include neonatal pharmacokinetics of antiretroviral agents and pharmacokinetics of anti-infectives in pregnant women. She is currently Chair of several IMPAACT (International Maternal Pediatric Adolescent AIDS Clinical Trials Network, NIH) protocols and a member of the IMPAACT Scientific Treatment Committee.



IMPAACT 2023: A Phase I Study of the Safety and Pharmacokinetics of Dolutegravir in Neonates Exposed to HIV-1
07/01/2022 - 06/30/2025 (Subcontract PI)
PI: Diana F. Clarke, PharmD
Johns Hopkins University ViiV Healthcare


IMPAACT Protocol Leadership: 2032 Protocol Vice Chair Remdesevir
07/01/2023 - 11/30/2023 (Subcontract PI)
PI: Diana F. Clarke, PharmD
Johns Hopkins University NIH NIAID
5UM1AI068632-17

IMPAACT 2032: Pharmacokinetics and Safety of Remdesivir for Treatment of COVID-19 in Pregnant and Non-Pregnant Women in the United States
12/01/2021 - 06/30/2023 (Subcontract PI)
PI: Diana F. Clarke, PharmD
Johns Hopkins University Gilead Sciences


LOC-IMPAACT Leadership Group: Pharmacokinetics and Safety of Remdesivir for Treatment of COVID-19 in Pregnant Women in the US
06/01/2020 - 11/30/2022 (Subcontract PI)
PI: Diana F. Clarke, PharmD
Johns Hopkins University NIH NIAID
3UM1AI068632-14S2

LOC-IMPAACT Leadership Group - IMPAACT 2023/P1097 Protocol Chair
12/01/2018 - 06/30/2022 (Subcontract PI)
PI: Diana F. Clarke, PharmD
Johns Hopkins University NIH NIAID


LOC-IMPAACT Leadership Group - Merck 1097P
01/01/2020 - 12/31/2020 (Subcontract PI)
PI: Diana F. Clarke, PharmD
Johns Hopkins University Merck


P1097A – TO# LDR 04 MOD 03 – Raltegravir Pharmacokinetics and Safety in Neon…..
01/01/2014 - 11/30/2020 (PI)
Johns Hopkins University Merck

P1097A - TO# LDR 04 MOD 02 - Raltegravir Pharmacokinetics and Safety in Neonates
01/01/2014 - 10/01/2020 (PI)
Johns Hopkins University NIH-NIAID

LOC-IMPAACT Leadership Group - JHU P1097 and P1110
01/01/2014 - 11/30/2015 (PI)
Johns Hopkins University NIH-NIAID
5 UM1 AI068632-09

IMPAACT Leadership Award: Chair, Protocol P1097
06/01/2012 - 12/31/2013 (PI)
Johns Hopkins University NIH-NIAID

Showing 10 of 14 results. Show All Results

Title


Yr Title Project-Sub Proj Pubs

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Rozen Eisenberg I, Campbell JI, Clarke D, Cooper ER, Pelton SI, Vuppula SS. Practice Variability in Uptake and Implementation of New U.S. DHHS Guidelines for Feeding of HIV-Exposed Infants. J Pediatric Infect Dis Soc. 2025 Jan 20; 14(1).View Related Profiles. PMID: 39726301; PMCID: PMC11744778; DOI: 10.1093/jpids/piae133;
     
  2. Brooks KM, Baltrusaitis K, Clarke DF, Nachman S, Jao J, Purswani MU, Agwu A, Beneri C, Deville JG, Powis KM, Stek AM, Eke AC, Shapiro DE, Capparelli E, Greene E, George K, Yin DE, Jean-Philippe P, Chakhtoura N, Bone F, Bacon K, Johnston B, Reding C, Kersey K, Humeniuk R, Best BM, Mirochnick M, Momper JD. Pharmacokinetics and Safety of Remdesivir in Pregnant and Nonpregnant Women With COVID-19: Results From IMPAACT 2032. J Infect Dis. 2024 Oct 16; 230(4):878-888.View Related Profiles. PMID: 38839047; PMCID: PMC11481345; DOI: 10.1093/infdis/jiae298;
     
  3. Bekker A, Capparelli EV, Mirochnick M, Clarke DF, Cotton MF, Shapiro R, McCarthy K, Moye J, Violari A, Chokephaibulkit K, Abrams E, Penazzato M, Ruel TD, Cressey TR. Lamivudine dosing for preterm infants exposed to HIV: a population pharmacokinetic modelling and simulation study. J Antimicrob Chemother. 2024 Oct 01; 79(10):2570-2574.View Related Profiles. PMID: 39092932; PMCID: PMC11441998; DOI: 10.1093/jac/dkae259;
     
  4. Liu XI, Dallmann A, Brooks K, Best BM, Clarke DF, Mirochnick M, van den Anker JN, Capparelli EV, Momper JD. Physiologically-based pharmacokinetic modeling of remdesivir and its metabolites in pregnant women with COVID-19. CPT Pharmacometrics Syst Pharmacol. 2023 Feb; 12(2):148-153.View Related Profiles. PMID: 36479969; PMCID: PMC9877749; DOI: 10.1002/psp4.12900;
     
  5. Piscitelli J, Nikanjam M, Best BM, Acosta E, Mirochnick M, Clarke DF, Capparelli EV, Momper JD. Optimizing Dolutegravir Initiation in Neonates Using Population Pharmacokinetic Modeling and Simulation. J Acquir Immune Defic Syndr. 2022 01 01; 89(1):108-114.View Related Profiles. PMID: 34629412; PMCID: PMC8665018; DOI: 10.1097/QAI.0000000000002830;
     
  6. Epstein RL, Penwill N, Clarke DF, Hamilton S, Horbowicz K, Dorfman D, Moses JM, Cooper ER. "Meds-in-Hand" Intervention to Reduce Critical Process Delays in Pediatric Human Immunodeficiency Virus Post-Exposure Prophylaxis. J Pediatric Infect Dis Soc. 2021 Mar 26; 10(2):196-200.View Related Profiles. PMID: 32347312; PMCID: PMC7996639; DOI: 10.1093/jpids/piaa033;
     
  7. Clarke DF, Lommerse J, Acosta EP, Cababasay MP, Wang J, Spector SA, Chain A, Smith E, Teppler H, Hazra R, Calabrese K, Graham B, Popson S, Bryson Y, Mirochnick M. Impact of Low Birth Weight and Prematurity on Neonatal Raltegravir Pharmacokinetics: Impaact P1097. J Acquir Immune Defic Syndr. 2020 12 15; 85(5):626-634.View Related Profiles. PMID: 32925360; PMCID: PMC8043209; DOI: 10.1097/QAI.0000000000002492;
     
  8. Clarke DF, Acosta EP, Cababasay M, Wang J, Chain A, Teppler H, Popson S, Graham B, Smith B, Hazra R, Calabrese K, Bryson Y, Spector SA, Lommerse J, Mirochnick M. Raltegravir (RAL) in Neonates: Dosing, Pharmacokinetics (PK), and Safety in HIV-1-Exposed Neonates at Risk of Infection (IMPAACT P1110). J Acquir Immune Defic Syndr. 2020 05 01; 84(1):70-77.View Related Profiles. PMID: 31913995; PMCID: PMC7144886; DOI: 10.1097/QAI.0000000000002294;
     
  9. Clarke DF, Mirochnick M, Acosta EP, Capparelli E, Chain A, Teppler H, Smith B, Lommerse J. Use of Modeling and Simulations to Determine Raltegravir Dosing in Neonates: A Model for Safely and Efficiently Determining Appropriate Neonatal Dosing Regimens: IMPAACT P1110. J Acquir Immune Defic Syndr. 2019 12 01; 82(4):392-398.View Related Profiles. PMID: 31658182; PMCID: PMC6820708; DOI: 10.1097/QAI.0000000000002149;
     
  10. Schreiner CN, Ahlfors CE, Wong RJ, Stevenson DK, Clarke DF, Mirochnick M. In Vitro Study on the Effect of Maraviroc or Dolutegravir on Bilirubin to Albumin Binding. Pediatr Infect Dis J. 2018 09; 37(9):908-909.View Related Profiles. PMID: 29561509
     
Showing 10 of 19 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 19 publications over 14 distinct years, with a maximum of 2 publications in 2000 and 2017 and 2020 and 2022 and 2024

YearPublications
19931
20002
20101
20111
20131
20141
20172
20181
20191
20202
20211
20222
20242
20251

Contact for Mentoring:

72 E. Concord St Instructional (L)
Boston MA 02118
Google Map

617.638.5300
Download vCard

Clarke's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
See all (89) concept(s)
_
Co-Authors
See all (9) people
_
Similar People
See all (60) people
_
Same Department
Search Department